Publications

Scientific literature on transforming growth factor-beta2 (TGF-β2) inhibition in malignant tumors:

• Schlingensiepen, K.-H. et. al., Targeted Downregulation of TGF-beta 2 with AP 12009 in Tumor Therapy, From: Cancer Drug Discovery and Development: Transforming Growth Factor-beta in Cancer Therapy, Vol II: Cancer Treatment and Therapy, Chapter 38, Pages 635-651, Humana Press Inc. (2008)

• Schlingensiepen, K.-H. et. al., Antisense Therapeutics for Tumor Treatment - The TGF-beta2 Inhibitor AP 12009 in Clinical Development against Malignant Tumors, From: Pancreatic Cancer, Part III: New Treatment Strategies and Outlook, Chapter 16, Pages 137-150, Springer (2008)

• Schlingensiepen K.-H. et al., Antisense-Nukleinsäuren in der Therapie maligner Tumoren. In: Zeller WJ, zur Hausen H, editors. Onkologie: Grundlagen - Diagnostik - Therapie - Entwicklungen. Landsberg/Lech: Ecomed; 2010. p. IV-20.

• Bogdahn U. et al., Targeted Therapy for High-Grade Glioma with the TGF-β2 Inhibitor Trabedersen: Results of a Randomized and Controlled Phase IIb Study. Neuro-Oncology, 2010, in press.

• Hau, P. and Jachimczak P. et. al., Inhibition of  TGF-beta2 with AP 12009 in recurrent malignant glioma:
  From preclinical to Phase I/II studies, Oligonucleotides 17 (2007): 201-212

• Schlingensiepen, K.-H. et. al., Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009, Cytokine Growth Factor Reviews 17 (2006): 129-139

• Schlingensiepen, R. et. al., Intracerebral and Intrathecal Infusion of the TGF-beta2-Specific Antisense Phosphorothioate Oligonucleotide AP 12009 in Rabbits and Primates: Toxicology and Safety,
  Oligonucleotides 15 (2005): 94-104

• Schlingensiepen, R. et. al., Immuntherapie gegen Maligne Tumore mit Antisense AP 12009:
  Technologie, Target, Therapie, Journal Onkologie 07 (2005): 24-30

• Jachimczak, P. et al., Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides, Int J Cancer 65 (1996): 332-337

• Jachimczak, P. et al., The effect of transforming growth factor-beta 2-specific phosphorothioate-antisense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma,
  J Neurosurg 78 (1993): 944-951

Recommended for further reading:

• Akhurst, R. J., Large- and small-molecule inhibitors of transforming growth factor-beta signaling,
  Curr Op Invest Drugs 7 (2006): 513-521

• Seoane J. The TGF-β pathway as a therapeutic target in cancer. Clin Transl Oncol. 2008 Jan;10(1):14-9.

• Padua D & Massague J. Roles of TGF-β in metastasis. Cell Res. 2009 Jan;19(1):89-102